Edition:
United Kingdom

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

9.96USD
4:06pm GMT
Change (% chg)

$0.38 (+3.97%)
Prev Close
$9.58
Open
$9.77
Day's High
$10.10
Day's Low
$9.50
Volume
58,147
Avg. Vol
56,977
52-wk High
$15.65
52-wk Low
$6.38

Chart for

About

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb... (more)

Overall

Beta: --
Market Cap(Mil.): $270.64
Shares Outstanding(Mil.): 22.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

10 Jan 2018

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update

07 Nov 2017

BRIEF-Syndax announces $25 million registered direct offering of common stock

* Syndax announces $25 million registered direct offering of common stock

17 Oct 2017

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing

17 Oct 2017

BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer

* ‍Syndax announces dosing of first patient in pivotal trial of entinostat for treatment of advanced or recurrent breast cancer in Japan by partner kyowa hakko kirin​

05 Oct 2017

BRIEF-Syndax Pharmaceuticals Q2 loss per share $0.70

* Syndax Pharmaceuticals reports second quarter 2017 financial results and provides clinical and business update

10 Aug 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.81 -0.18
Novartis AG (NOVN.S) CHF83.02 +0.12
Eli Lilly and Co (LLY.N) $85.85 +0.03

Earnings vs. Estimates